Cancer chemotherapy in clinical practice

Cancer Chemotherapy in Clinical Practice

Volumn , Issue , 2008, Pages 1-129

  Priestman, Terry ^a  

^a NEW CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892325163     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-84628-991-0     Document Type: Book

References (9)

1. Gasco M, Argusti A, Bonanni B, Decensi A. SERMs in chemoprevention of breast cancer. Eur J Cancer, 2005; 41: 1980-1989.
2. O'Regan RM. Breast cancer chemoprevention. Lancet, 2005; 366: 1506-1508.
3. Mellon JK. The finasteride prostate cancer prevention trial (PCPT)-what have we learned? Eur J Cancer, 2005; 2016-2022.
4. Ng R, Better N, Green MD. Anti-cancer agents and cardiotoxicity. Semin Oncol, 2006; 33: 2-14.
5. Sipples R. Common side effects of anti-EGFR therapy: acneform rash. Semin Oncol Nursing, 2006; 22: 28-34.
6. ESMO. Minimum clinical recommendations for diagnosis, treatment and follow-up of multiple myeloma. Annals Oncol, 2005; 16 (supplement 1): i45-i47.
7. NICE. NICE appraisal of bortezomib for the treatment of relapsed and refractory multiple myeloma. October 2006. www. nice. org. uk
8. Siroki B, Powles R. Multiple myeloma. Lancet 2004; 363: 875-887.
9. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2005; 132: 410-451.